FXR Agonist Combination Therapy for Severe Hyperlipidemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for elevated lipid levels in the blood, such as cholesterol and triglycerides, are inadequate for many patients due to drug resistance, adverse effects, and inadequate efficacy when administered alone, necessitating a need for improved combination therapies.
Innovation Solution
A pharmaceutical composition comprising an FXR agonist in combination with PPAR-alpha, PPAR-delta, or PPAR-alpha and delta dual agonists, fibrates, or statins, optionally with pharmaceutically acceptable carriers, to synergistically lower lipid levels and reduce liver enzyme levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a fibric acid derivative is used alone to treat hyperlipidemia, then the treatment can be simple and the side effect profile is manageable, but the efficacy is inadequate for severe hyperlipidemia
Solution Approach 1:
The patent combines a fibric acid derivative with another lipid-lowering agent (such as a statin, niacin, or ezetimibe) into a single pharmaceutical composition. This merging of multiple therapeutic agents addresses the inadequacy of monotherapy for severe hyperlipidemia while providing synergistic lipid-lowering effects that improve efficacy without requiring the patient to take multiple separate medications.
2Object-affected harmful factors
If the dose of fibric acid derivative is reduced to improve side effect profile, then adverse effects are minimized, but efficacy is compromised
Solution Approach 1:
By combining a lower dose of fibric acid derivative with complementary lipid-lowering agents in a fixed-dose combination product, the patent achieves adequate lipid control while reducing the dose-related side effects of the fibric acid derivative. The synergistic action of multiple agents allows for dose reduction of individual components.
Solution Approach 2:
The pharmaceutical composition creates a composite therapeutic formulation that integrates multiple lipid-lowering mechanisms of action. This composite approach allows the different agents to work together synergistically, providing effective lipid control at lower doses of each individual agent, thereby reducing adverse effects while maintaining or improving overall efficacy.
3Reliability
If multiple lipid-lowering agents are combined to improve efficacy, then lipid control is enhanced, but the treatment complexity and potential for drug interactions increase
Solution Approach 1:
The patent merges multiple lipid-lowering agents into a single pharmaceutical composition with fixed dosages of each component. This approach enhances lipid control through synergistic mechanisms while simplifying treatment by providing a single pill solution, thereby reducing pill burden and improving patient compliance without requiring complex dosing regimens.
Solution Approach 2:
The combined pharmaceutical composition serves multiple therapeutic functions simultaneously - lowering different types of lipids through different mechanisms of action - within a single agent system. This multi-functionality addresses various aspects of dyslipidemia comprehensively while maintaining treatment simplicity.
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.